FDA Approval

NMT Group PLC
27 November 2001


27 November 2001

                                NMT GROUP PLC

        1cc Insulin Syringe Granted FDA Section 510(k) Approval in USA

NMT Group PLC ('NMT'), the manufacturer of retractable devices to prevent
needlestick injury, announces today that it has received approval from the US
Food and Drug Administration (FDA) under Section 510(k) of the Food, Drug and
Cosmetic Act to market and sell its 1cc insulin syringe in the USA. Insulin
syringes, used to deliver insulin in controlling diabetes, represent a
substantial proportion of the total US disposable syringe market which has
been estimated at 6.6 billion units.


Commenting on today's news, Roy Smith, Chief Executive of NMT, said:


'The receipt of notification of FDA approval for our 1cc Insulin safety
syringe should allow commercial sales to start in early 2002. This approval is
yet another positive step towards the future success of the Group'


Enquiries:

NMT Group PLC
Roy Smith, Chief Executive Officer                  Tel: [phone]
Gerard Cassels, Finance Director                    Tel: [phone]


Financial Dynamics                                  Tel: [phone]
David Yates/Fiona Noblet





This announcement has been approved by WestLB Panmure Limited solely for the
purposes of section 57 of the Financial Services Act 1986. It does not
constitute an offer or invitation to purchase or sell any securities.


WestLB Panmure Limited, which is regulated by The Securities and Futures
Authority Limited, is acting exclusively for NMT Group plc and will not be
responsible to anyone other than NMT Group plc for providing the protections
afforded to customers of WestLB Panmure Limited nor for providing advice in
relation to the contents of this announcement or any matter referred to
herein.


This press announcement is not for distribution in or into the United States,
Canada, the Republic of Ireland, Australia or Japan.